In the ELIANA study of a CD19 targeting CAR for B-ALL, 7.6% of patients did not receive the CAR T cells due to ‘product related issues’, whereby it was not possible to manufacture a sufficient number of CAR T cells for infusion [35]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.